Trestle Biotherapeutics is developing implantable bioengineered tissues using stem cell biology and biofabrication techniques to provide a functional therapeutic solution for patients with end-stage renal disease. This approach aims to eliminate the need for dialysis and delay kidney transplantation, addressing the critical shortage of treatment options for the 850 million people affected by kidney disease globally.
Funding
$130K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
KIFounders
Product
Problem
Patients with end-stage renal disease have limited treatment options, primarily relying on dialysis or kidney transplantation. Dialysis, while life-sustaining, presents significant medical risks and negatively impacts the patient's quality of life. The shortage of available kidneys for transplantation further exacerbates the problem, leaving many patients without optimal treatment.
Solution
Trestle Biotherapeutics is developing implantable bioengineered tissues as a therapeutic solution for end-stage renal disease. These stem cell-derived tissues are designed to restore renal function, potentially eliminating the need for dialysis and delaying or even replacing the need for kidney transplantation. The bioengineered tissues are created using advanced 3D biofabrication techniques, allowing for precise control over tissue structure and function. By integrating stem cell biology and biofabrication, Trestle aims to provide a functional and long-lasting solution for patients with kidney failure. The company is also part of the Wellcome Leap HOPE program, which focuses on bioengineering complex human organs and immune system interactions.
Target Audience
The primary target audience includes patients with end-stage renal disease who are currently undergoing dialysis or are awaiting kidney transplantation.
Features
- Development of implantable bioengineered kidney tissues derived from stem cells
- Utilization of 3D biofabrication techniques for precise tissue engineering
- Designed to restore renal function and reduce or eliminate dialysis dependency
- Aims to delay or replace the need for kidney transplantation
- Integration of developmental & stem cell biology with 3D biofabrication technologies
- Part of the Wellcome Leap HOPE program focused on bioengineering complex human organs